Participation of Complement 3a receptor (C3aR) in the sensitization phase of Th2 mediated allergic contact dermatitis

Experimental Dermatology

Volumn 21, Issue 1, 2012, Pages 52-56

  Niebuhr, Margarete ^a   Bäumer, Wolfgang ^b   Kietzmann, Manfred ^b   Wichmann, Katja ^a   Heratizadeh, Annice ^a   Werfel, Thomas ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

Allergic contact dermatitis; Anaphylatoxin; Complement 3a; Complement 3a receptor; T cell

Indexed keywords

COMPLEMENT COMPONENT C3A; COMPLEMENT RECEPTOR; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; TOLUENE DIISOCYANATE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONTACT DERMATITIS; CONTACT SENSITIVITY; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE MODEL; IMMUNE RESPONSE; IN VIVO STUDY; LOCAL LYMPH NODE ASSAY; MOUSE; NONHUMAN; SKIN ALLERGY; SKIN SENSITIZATION; SKIN SWELLING; SPLEEN CELL;

ANIMALS; CYTOKINES; DERMATITIS, CONTACT; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; RECEPTORS, COMPLEMENT; TH2 CELLS; TOLUENE 2,4-DIISOCYANATE;

EID: 83455223800     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2011.01403.x     Document Type: Article

References (25)

1. Coenraads P J, Goncalo M. Eur J Dermatol 2007: 17: 564.
2. Lass C, Merfort I, Martin S F. Exp Dermatol 2010: 19: 1007-10013.
3. Vocanson M, Hennino A, Rozieres A et al. Allergy 2009: 64: 1699-1714.
4. Klos A, Tenner A J, Johswich K O et al. Mol Immunol 2009: 46: 2753-2766.
5. Gutzmer R, Lisewski M, Zwirner J et al. Immunology 2004: 111: 435-443.
6. Purwar R, Wittmann M, Zwirner J et al. J Immunol 2006: 177: 4444-4450.
7. Zwirner J, Gotze O, Begemann G et al. Immunology 1999: 97: 166-172.
8. Daffern P J, Pfeifer P H, Ember J A et al. J Exp Med 1995: 181: 2119-2127.
9. Nilsson G, Johnell M, Hammer C H et al. J Immunol 1996: 157: 1693-1698.
10. Grabbe S, Schwarz T. Immunol Today 1998: 19: 37-44.
11. Takabayashi T, Vannier E, Burke J F et al. J Infect Dis 1998: 177: 1622-1628.
12. Kildsgaard J, Hollmann T J, Matthews K W et al. J Immunol 2000: 165: 5406-5409.
13. Fischer M B, Ma M, Goerg S et al. J Immunol 1996: 157: 549-556.
14. Kawamoto S, Yalcindag A, Laouini D et al. J Clin Invest 2004: 114: 399-407.
15. Liu J, Lin F, Strainic M G et al. J Immunol 2008: 180: 5882-5889.
16. Akiba H, Kehren J, Ducluzeau M T et al. J Immunol 2002: 168: 3079-3087.
17. Purwar R, Bäumer W, Niebuhr M et al. Exp Dermatol: 2011: 20: 709-714.
18. Bäumer W, Seegers U, Braun M et al. Br J Dermatol 2004: 151: 823-830.
19. Ehling G, Hecht M, Heusener A et al. Toxicology 2005: 212: 60-68.
20. Reines I, Kietzmann M, Mischke R et al. J Invest Dermatol 2009: 129: 1954-1962.
21. Bäumer W, Gorr G, Hoppmann J et al. Eur J Pharmacol 2002: 446: 195-200.
22. Dong C. Eur J Immunol 2009: 39: 640-644.
23. Albanesi C, Scarponi C, Cavani A et al. J Invest Dermatol 2000: 115: 81-87.
24. Pennino D, Eyerich K, Scarponi C et al. J Immunol 2010: 184: 4880-4888.
25. Banerjee G, Damodaran A, Devi N et al. Scand J Immunol 2004: 59: 385-394.